Study Condition(s): Atopic Dermatitis

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Study Alias: JAHG

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02576938 {{ currentLocaleObject.registryAnchorText }}

Completed Completed

Study Purpose

The purpose of this study is to evaluate the safety and effectiveness of baricitinib in people with eczema.

Completed Study

The results of this study are not yet available.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18+ years

Time Commitment

Your participation could last up to 28 weeks and include 8 visits to the study center.
  • Participant must have moderate-to-severe Atopic Dermatitis (AD)

  • Participant must have a history of inadequate clinical response to other eczema treatments

  • Participant must agree to use adequate contraception

  • Female participant must not be pregnant or nursing

  • Participant must not have skin conditions such as psoriasis or lupus erythematosus or a skin disease that requires frequent hospitalizations or IV treatment

  • Participant must not have compromised immunity

  • Participant must not have active or latent tuberculosis, HIV, Hepatitis B, Hepatitis C or chronic liver disease

Where This Study Took Place Tool Tip Icon

13 locations participated
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.